Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
alemtuzumab cambridge pathology 1 antigen NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 509.21 approved inhibitor
alemtuzumab cambridge pathology 1 antigen NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 509.21 approved unknown
alemtuzumab campath-1 antigen biotech NA drugbank , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 509.21 approved,investigational antibody
alemtuzumab campath-1 antigen biotech NA drugbank , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 509.21 approved,investigational antibody,inhibitor
alemtuzumab cambridge pathology 1 antigen NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 509.21 approved antibody
alemtuzumab high affinity immunoglobulin gamma fc receptor i biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
alemtuzumab low affinity immunoglobulin gamma fc region receptor ii-a biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
alemtuzumab low affinity immunoglobulin gamma fc region receptor ii-b biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
alemtuzumab low affinity immunoglobulin gamma fc region receptor ii-c biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
alemtuzumab low affinity immunoglobulin gamma fc region receptor iii-a biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
alemtuzumab low affinity immunoglobulin gamma fc region receptor iii-b biotech NA drugbank Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]		 NA approved,investigational unknown
click here to return to the previous page